Japanese pharma group Otsuka has signed an agreement to acquire Canada's Mindset Pharma, a specialist in psychedelic medicines for neuropsychiatric disorders.
Despite the growing interest in developing medicines based on psychedelic compounds, big pharma has seemed a bit wary of getting involved, leaving the task to small start-ups.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh